Sugi Predict

Sugi Predict / Compounds / SCHEMBL10021900

SCHEMBL10021900

SCHEMBL10021900

CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](N)CO[C@@H]1OC(CO)[C@@H](O[C@@H]2OC(CO)[C@H](O[C@@H]3OC(CO)[C@H](O)[C@H](O[C@@H]4OC(CO)[C@H](O)[C@H](O)C4O)C3N)[C@H](O[C@]3(OC=O)C[C@@H](O)[C@@H](N)C([C@H](O)[C@H](O)CO)O3)C2O)[C@H](O)C1O

nearest known ligand 0.52

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ CETP P11597 1/20 0.52
▸ SELL P14151 3/20 0.38
▸ SELP P16109 6/20 0.37
▸ SIGLEC7 Q9Y286 4/20 0.36
▸ APP P05067 1/20 0.34
▸ SELE P16581 1/20 0.34
▸ MAG P20916 3/20 0.34
▸ GJB2 P29033 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10021890 0.91 CETP (0.52) CETPSELLSELPSIGLEC7APP
SCHEMBL10021888 0.82 SELP (0.53) CETPSELLSELPSIGLEC7APP
SCHEMBL10021889 0.80 SELP (0.55) CETPSELLSELPSIGLEC7APP
SCHEMBL17789071 0.80 SELP (0.54) CETPSELLSELPSIGLEC7APP
SCHEMBL10021893 0.80 SELP (0.57) CETPSELLSELPSIGLEC7APP
SCHEMBL10021896 0.79 SELP (0.51) CETPSELLSELPSIGLEC7APP
SCHEMBL10021894 0.79 SELP (0.53) CETPSELLSELPSIGLEC7APP
SCHEMBL29435363 0.79 SIGLEC7 (0.58) CETPSELLSELPSIGLEC7SELE
SCHEMBL17789072 0.77 SELP (0.51) CETPSELLSELPSIGLEC7APP
SCHEMBL17789070 0.77 SELP (0.51) CETPSELLSELPSIGLEC7APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160151401-A1 GLYCOLIPIDS AS TREATMENT FOR DISEASE LA JOLLA PHARMACEUTICAL COMPANY 2016-06-02 — — US disclosed
US-20120035120-A1 GLYCOLIPIDS AS TREATMENT FOR DISEASE SENEB BIOSCIENCES, INC. (US) 2012-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035120-A1 GLYCOLIPIDS AS TREATMENT FOR DISEASE GBA2, UGCG, GBA1 CETP 571/4885SELL 2166/4885SELP 2417/4885
US-20160151401-A1 GLYCOLIPIDS AS TREATMENT FOR DISEASE GBA2, UGCG, GBA1 CETP 571/4885SELL 2166/4885SELP 2417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback